Bortezomib prevents the expression of MMP-13 and the degradation of collagen type 2 in human chondrocytes

Biochemical and Biophysical Research Communications

Volumn 452, Issue 3, 2014, Pages 526-530

  Hu, Weihua ^a   Zhang, Weikai ^a   Li, Feng ^a   Guo, Fengjing ^a   Chen, Anmin ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Interferon response factor 1 (IRF 1); Matrix metalloproteinase 13; Osteoarthritis; TNF ; Type II collagen

Indexed keywords

BORTEZOMIB; COLLAGEN TYPE 2; COLLAGENASE 3; INTERFERON REGULATORY FACTOR 1; JANUS KINASE 2; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; STAT1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; BORONIC ACID DERIVATIVE; JAK2 PROTEIN, HUMAN; PROTEASOME; PROTEASOME INHIBITOR; PYRAZINE DERIVATIVE; STAT1 PROTEIN, HUMAN;

ARTICLE; CARTILAGE CELL; CELL ISOLATION; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME INHIBITION; FLUORESCENCE MICROSCOPY; GENE INDUCTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OSTEOARTHRITIS; PATHOLOGY; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION;

BORONIC ACIDS; CHONDROCYTES; COLLAGEN TYPE II; GENE EXPRESSION REGULATION; HUMANS; INTERFERON REGULATORY FACTOR-1; JANUS KINASE 2; MATRIX METALLOPROTEINASE 13; OSTEOARTHRITIS; PRIMARY CELL CULTURE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PROTEOLYSIS; PYRAZINES; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84907559775     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.08.102     Document Type: Article

References (21)

1. A.R. Poole, M. Kobayashi, and T. Yasuda Type II collagen degradation and its regulation in articular cartilage in osteoarthritis Ann. Rheum. Dis. 61 2 2002 ii78 ii81
2. F. Nelson, L. Dahlberg, and S. Laverty Evidence for altered synthesis of type II collagen in patients with osteoarthritis J. Clin. Invest. 102 1998 2115 2125
3. T. Shiomi, V. Lemaître, J. D'Armiento, and Y. Okada Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases Pathol. Int. 60 2010 477 496
4. H. Lim, and H.P. Kim Matrix metalloproteinase-13 expression in IL-1β-treated chondrocytes by activation of the p38 MAPK/c-Fos/AP-1 and JAK/STAT pathways Arch. Pharm. Res. 34 2011 109 117
5. T. Taniguchi, K. Ogasawara, and A. Takaoka IRF family of transcription factors as regulators of host defense Annu. Rev. Immunol. 19 2001 623 655
6. P. Barr, R. Fisher, and J. Friedberg The role of bortezomib in the treatment of lymphoma Cancer Invest. 25 2007 766 775
7. U. Heider, J. Rademacher, and B. Lamottke Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma Eur. J. Haematol. 82 2009 440 449
8. D.C. Duffey, Z. Chen, and G. Dong Expression of a dominant-negative mutant inhibitor-κBα of nuclear factor-κB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression and tumor growth in vivo Cancer Res. 59 1999 1999 3468 3474
9. F.T. Chen, Y.C. Liu, C.M. Yang, and C.H. Yang Anti-inflammatory effect of the proteasome inhibitor bortezomib on endotoxin-induced uveitis in rats Invest. Ophthalmol. Vis. Sci. 53 2012 3682 3694
10. F. Zhou, L. Zhang, and K. Gong LEF-1 activates the transcription of E2F1 Biochem. Biophys. Res. Commun. 365 2008 149 153
11. K.A. Elsaid, and C.O. Chichester Review: collagen markers in early arthritic diseases Clin. Chim. Acta 365 2006 68 77
12. A.P. Hollander, I. Pidoux, and A. Reiner Damage to type II collagen in aging and osteoarthritis starts at the articular surface, originates around chondrocytes, and extends into the cartilage with progressive degeneration J. Clin. Invest. 96 1995 2859 2869
13. A.R. Poole, and D.S. Howell Etiopathogenesis of osteoarthritis R.W. Moskowitz, D.S. Howell, V.M. Goldberg, H.J. Mankin, Osteoarthritis: Diagnosis, and Management 3rd ed. 2001 Saunders Philadelphia 29 47
14. T. Tamura, H. Yanai, and D. Savitsky The IRF family transcription factors in immunity and oncogenesis Annu. Rev. Immunol. 26 2008 535 584
15. H. Lim, and H.P. Kim Matrix metalloproteinase-13 expression in IL-1b-treated chondrocytes by activation of the p38 MAPK/c-Fos/AP-1 and JAK/STAT pathways Arch. Pharm. Res. 34 2011 109 117
16. A.M. Roccaro, A. Vacca, and D. Ribatti Bortezomib in the treatment of cancer Recent Pat. Anticancer Drug. Discov. 1 2006 397 403
17. F. Yang, V. Jove, and S. Chang Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-κB signaling, and synergizes with an ERK inhibitor Cancer Biol. Ther. 13 2012 349 357
18. T. Tamatani, N. Takamaru, and K. Hara Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells Int. J. Oncol. 42 2013 935 944
19. M. Colonna TLR pathways and IFN-regulatory factors: to each its own Eur. J. Immunol. 37 2007 306 309
20. H. Lu, C. Zeng, H. Zhao, L. Lian, and Y. Dai Glatiramer acetate inhibits degradation of collagen II by suppressing the activity of interferon regulatory factor-1 Biochem. Biophys. Res. Commun. 448 2014 323 328
21. C.Y. Huang, K.Y. Lai, and L.F. Hung Advanced glycation end products cause collagen II reduction by activating Janus kinase/signal transducer and activator of transcription 3 pathway in porcine chondrocytes Rheumatology (Oxford) 50 2011 1379 1389